Therapy Areas: Oncology
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering u...
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination
19 November 2025 - US-based pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has received approval from the US Food and Drug Administration for EPKINLY (epcoritamab-bysp), a T-ce...
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
18 November 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Tuesday that its Phase III lidERA trial of giredestrant met its primary endp...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the...
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
18 November 2025 - Clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) on Monday announced results from its joint research with Virginia Commonwealth University (VCU) eva...
Privo Technologies reports positive results from non-invasive oral cancer and high-grade dysplasia trial
18 November 2025 - Privo Technologies, a US-based late-stage clinical biopharmaceutical company, on Monday reported results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoenginee...
Related Headlines

BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen

EirGenix signs second global exclusive licensing deal with Sandoz

Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s

ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines

Shilpa Medicare completes fourth complex clinical program with positive topline Phase three results for Shilpa's OERIS

iLeukon Therapeutics reveals new clinical results for ILKN421H ongoing first-in-human Phase I trial (NCT05978102)

enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial

FDA approves Promega OncoMate MSI Dx Analysis System as companion diagnostic for KEYTRUDA and LENVIMA in advanced endometrial carcinoma

QIAGEN launches QIAsymphony Connect and showcases new precision oncology advances at AMP 2025

Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL

AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding

Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests

Akeso reveals preclinical research data for novel antagonistic monoclonal antibody aimed at IL-1RAP (AK135)

Boehringer Ingelheim receives Commissioner's National Priority Voucher for HERNEXEOS (zongertinib tablets)

Evinova China and Harbour BioMed form AI partnership to accelerate biologics development